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Abstract   
Studies have examined the associations between cancers and circulating 25-hydroxyvitamin 
D [25(OH)D], but little is known about the impact of different laboratory practices on 
25(OH)D concentrations. We examined the potential impact of delayed blood centrifuging, 
choice of collection tube, and type of assay on 25(OH)D concentrations. Blood samples from 
20 healthy volunteers underwent alternative laboratory procedures: four centrifuging times 
(2, 24, 72, and 96 h after blood draw); three types of collection tubes (red top serum tube, two 
different plasma anticoagulant tubes containing heparin or EDTA); and two types of assays 
(DiaSorin radioimmunoassay [RIA] and chemiluminescence immunoassay 
[CLIA/LIAISON®]). Log-transformed 25(OH)D concentrations were analyzed using the 
generalized estimating equations (GEE) linear regression models. We found no difference in 
25(OH)D concentrations by centrifuging times or type of assay. There was some indication of 
a difference in 25(OH)D concentrations by tube type in CLIA/LIAISON®-assayed samples, 
with concentrations in heparinized plasma (geometric mean, 16.1 ng ml−1) higher than those 
in serum (geometric mean, 15.3 ng ml−1) (p = 0.01), but the difference was significant only 
after substantial centrifuging delays (96 h). Our study suggests no necessity for requiring 
immediate processing of blood samples after collection or for the choice of a tube type or 
assay.  
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Health and Human Services nor does mention of trade names, commercial products, or 
organization imply endorsement by the United States Government. 
 
Introduction 
Some epidemiologic studies [1–4], although not all [5–8], have suggested inverse 
associations between vitamin D concentrations and certain cancers. Studies of vitamin D 
have generally focused on circulating 25-hydroxyvitamin D [25(OH)D] as the ideal 
biomarker for vitamin D status. However, little is known about the impact of laboratory 
practices on 25(OH)D concentrations. Concerns have been raised regarding whether these 
differences affect the comparability of results across studies. In addition, if sample 
preparation practices differed by disease status (e.g., controls undergo more shipping delays 
than cases and thus have a longer lag between blood draw and centrifuging), and these 
differences affected 25(OH)D concentrations, differential bias might result.  
Epidemiologic studies of 25(OH)D vary in several laboratory practices that might affect 
25(OH)D concentrations, including (1) the time from blood draw to centrifuging, (2) choice 
of collection tube, and (3) type of 25(OH)D assay. For instance, in the Nurses’ Health Study, 
unprocessed blood samples were collected in tubes containing heparin as an anticoagulant 
and returned to their centralized facility via overnight shipping, with 97% of samples 
received within 26 h of draw for processing [1]. The Health Professionals Follow-Up study, 
which also processed blood samples at a centralized facility after overnight shipping, 
collected blood samples in tubes containing the anticoagulant sodium EDTA [9]. In the 
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, blood samples were 
collected in multiple tube types with 25(OH)D concentrations measured using samples 
collected in red top serum tubes, which were centrifuged within 2 h of blood draw (Mark 
Purdue, personal communication). Concerns have been raised regarding whether different 
blood processing procedures affect 25(OH)D measurements. Some have questioned whether 
delayed centrifuging reduces 25(OH)D stability due to hemolysis [10]. In addition, the choice 
of collection tube has been shown to affect the measurement for many analytes [11].  
A number of laboratory methods exist for 25(OH)D measurements, including the 
radioimmunoassay (RIA), competitive protein binding assays (CPBA), direct detection 
methodologies (e.g., high performance liquid chromatography [HPLC] and liquid 
chromatography–tandem mass spectroscopy [LC–MS/MS]), and automatic instrumentation 
methodologies (e.g., The DiaSorin LIAISON® platform and the Nicols Advantage® System) 
[12, 13]. Among these methods, DiaSorin RIA has been commonly used in large-scale 
epidemiologic studies. In recent years, there has been increasing interest in applying 
automated 25(OH)D assays, such as the DiaSorin chemiluminescence immunoassay 
(CLIA/LIAISON®), in epidemiologic studies. However, information on comparability of 
25(OH)D measurements across different assays remains limited.  
To address these issues, we conducted a methods study to systematically evaluate the 
potential impact on 25(OH)D concentrations from the time from blood draw to centrifuging 
(2, 24, 72, and 96 h after blood draw), choice of collection tubes (red top serum tube, two 
different anticoagulant tubes containing heparin or EDTA), as well as two of the most 
commonly used assays in epidemiologic studies (DiaSorin RIA and CLIA/LIAISON®).  
 
 
 
 
 
Materials and methods 
Study population 
The institutional review board at the National Cancer Institute approved the protocol. In 
March 2008, 20 healthy volunteers (and two additional volunteers for quality control) were 
enrolled in Maryland, USA. To increase the range of 25(OH)D concentrations, we enrolled 
volunteers of various racial groups/skin tones and included a subset of persons who had 
recently taken a sunny holiday in low latitudes (e.g., Florida, the Caribbean) because 
cutaneous production of vitamin D is related to the melanin content of the skin and recent sun 
exposure [2]. The recruiting center provided the following information on the 20 anonymous 
volunteers (7 males and 13 females; mean age = 46.3 years, range 26–63 years): 10 
Caucasians/light skin individuals (6 with recent sunny holiday trips), and 10 non-
Caucasians/non-light skin individuals (3 with recent sunny holiday trips).  
Blood processing 
We collected donor samples into three tube types: red top serum tubes (no additive), green-
topped plasma tubes (heparin as additive), and lavender-topped plasma tubes (EDTA as 
additive) (Fig. 1). Samples were randomized to avoid any potential bias from the order of 
collection and were subsequently assigned to one of each centrifuging times to simulate 
several field conditions—immediate processing (2 h), overnight shipping (24 h), weekend 
shipping (72 h), and delayed receipt of blood samples (96 h). Except for the samples 
centrifuged at 2 h after blood draw, which were retained on wet ice until centrifuging, other 
samples were placed in plastic canisters surrounded by −20°C gel-packs and stored in 
shipping boxes until centrifuging, to maintain the samples between 2 and 8°C until 
centrifugation. All blood samples were centrifuged at 1,200×g for 15 min at 10°C, aliquoted 
and stored at −70°C until shipment to Heartland Assays (Ames, IA) for 25(OH)D 
measurement. There were a total of 24 tubes from each volunteer (4 centrifuging times by 3 
collection tube types by 2 assays).  
 
Fig. 1 Blood sample collection and processing in 20 study volunteers  
 
25(OH)D assays 
Measurement of 25(OH)D was taken at one laboratory using CLIA/LIAISON® and RIA 
(both performed at Heartland Assays using commercially available kits from DiaSorin 
[Stillwater, MN]). The DiaSorin LIAISON® 25-OH vitamin D Total Assay System was used 
for the CLIA/LIAISON® assay. Details of the two assays have been described previously [14, 
15]. The limit of detection was 4.0 ng ml−1 for CLIA/LIAISON® and 2.5 ng ml−1 for 
DiaSorin RIA (for conversion to nmol l−1, 1 ng ml−1 = 2.496 nmol l−1). For both assays, each 
batch contained up to 100 samples. Thus, our samples were analyzed in three batches with 
samples from each volunteer included in the same batch. One laboratory investigator (RH), 
blinded to the centrifuging time and the type of sample, oversaw all laboratory analyses.  
Quality control (QC) 
We were allowed to include only a limited number of QC samples given our budget and the 
number of samples per batch. We decided to maximize the number of heparin tubes that were 
centrifuged at 2 h based on recommendations from other investigators. One QC volunteer 
was enrolled, with the volunteer’s blood collected in heparin tubes and centrifuged after 2 h. 
Samples from this QC volunteer were included as duplicates in each batch (for both RIA and 
CLIA/LIAISON®) to provide variance estimates associated with within- and between-batch 
variability. The statistical estimation procedure we used estimated all coefficient of variation 
(CV) parameters at one time. The within-batch and between-batch CV for CLIA/LIAISON® 
were 5.2 and 6.1%, respectively. For RIA, the within-batch CV was 11.1%, whereas the 
between-batch CV was outside our statistical constraint (we constrained this to 0), suggesting 
that the differences within batch accounted for all the measurable variability in RIA.  
Statistical analysis 
25(OH)D concentrations were logarithmically transformed, and the Pearson correlation 
coefficient (r) was calculated to examine the agreement between the concentrations measured 
by CLIA/LIAISON® and RIA. To assess the effects of delayed centrifuging time, type of 
collection tube, and type of 25(OH)D assay, we used generalized estimating equations (GEE) 
linear regression models [16], which account for the correlations between measures from the 
same individual, with the log-transformed 25(OH)D results as continuous outcomes. 
Explanatory variables included centrifuging time (four categories), collection tube (three 
categories), and type of 25(OH)D assay (two categories). Interaction between collection tube 
and centrifuging time on 25(OH)D concentrations was evaluated by creating cross-product 
terms. A priori, we decided to examine the effect of collection tube at the 2-hour and the 24-
hour centrifuging times, because they are common times before processing. All statistical 
tests were two-sided and performed using the SAS® statistical software (Cary, NC).  
 
Results 
Distribution of 25(OH)D concentrations 
The 25(OH)D concentrations in our study were generally lower than the proposed guideline 
of 20 ng ml−1 (or 50 nmol l−1) [17] (Table 1). The two assays gave comparable 25(OH)D 
values (Table 1), and the correlation between the two assays was high (r = 0.89). In addition, 
the type of assay had little effect on 25(OH)D concentrations in the GEE model (omnibus 
test, p = 0.37), after adjusting for centrifuging time and collection tube. 
Table 1 Geometric mean of 25(OH)D concentrations (ng ml−1) in 20 volunteers, by 
centrifuging time, collection tube, and type of assay  
  
2 h 24 h 72 h 96 h All times combined 
Geometric 
mean (range) 
Geometric 
mean (range) 
Geometric 
mean (range) 
Geometric 
mean (range) 
Geometric 
mean (range) 
Chemiluminescence immunoassay (CLIA/LIAISON®)  
 No 
additive—
serum 
15.4 (6.4, 
62.4) 
16.3 (6.3, 
64.5) 
14.5 (6.6, 
60.4) 
15.1 (5.4, 
59.0) 
15.3 (5.4, 
64.5) 
 Heparin—
plasma 
16.1 (6.3, 
61.6) 
16.7 (6.1, 
60.0) 
15.3 (6.4, 
56.1) 
16.6 (6.6, 
62.3) 
16.1 (6.1, 
62.3) 
 EDTA— 15.6 (6.3, 14.5 (6.9, 15.3 (7.0, 15.7 (6.1, 15.3 (6.1, 
  
2 h 24 h 72 h 96 h All times combined 
Geometric 
mean (range) 
Geometric 
mean (range) 
Geometric 
mean (range) 
Geometric 
mean (range) 
Geometric 
mean (range) 
plasma 63.5) 59.4) 58.1) 56.6) 63.5) 
 All tubes 
combined 
15.7 (6.3, 
63.5) 
15.8 (6.1, 
64.5) 
15.0 (6.4, 
60.4) 
15.8 (5.4, 
62.3) 
15.6 (5.4, 
64.5) 
Radioimmunoassay (DiaSorin RIA) 
 No 
additive—
serum 
16.0 (6.1, 
59.2) 
16.1 (6.7, 
57.8) 
16.7 (7.2, 
68.2) 
16.1 (5.9, 
58.3) 
16.2 (5.9, 
68.2) 
 Heparin—
plasma 
15.9 (5.4, 
53.8) 
16.4 (5.5, 
58.5) 
17.0 (7.6, 
58.9) 
16.9 (7.2, 
59.1) 
16.5 (5.4, 
59.1) 
 EDTA—
plasma 
15.5 (7.5, 
56.2) 
15.5 (5.0, 
65.1) 
16.1 (5.8, 
58.3) 
15.6 (5.3, 
54.8) 
15.7 (5.0, 
65.1) 
 All tubes 
combined 
15.8 (5.4, 
59.2) 
16.0 (5.0, 
65.1) 
16.6 (5.8, 
68.2) 
16.2 (5.3, 
59.1) 
16.1 (5.0, 
68.2) 
Abbreviations used CLIA Chemiluminescence immunoassay; RIA Radioimmunoassay  
CLIA/LIAISON®  
 
None of the 25(OH)D concentrations in our samples were below or close to the limit of 
detection (minimum, 5.4 ng ml−1 vs. limit of detection, 4.0 ng ml−1). We found no evidence 
of the effect of centrifuging time on 25(OH)D concentrations (Table 2). We found some 
indication of a difference in 25(OH)D concentrations by type of collection tube (Table 2). 
Pair-wise comparisons between tubes revealed that heparinized plasma had significantly 
higher 25(OH)D concentrations than serum (pair-wise test, p = 0.01) and marginally non-
significantly higher concentrations than EDTA plasma (pair-wise test, p = 0.08). The 
difference by tube was statistically significant only in samples centrifuged at 96 h (omnibus 
test, p = 0.05) but not in samples centrifuged earlier, including the two centrifuging times (2 
and 24 h) commonly used in large epidemiologic studies (data not presented). No significant 
interactions were found between centrifuging time and collection tube (data not presented). 
Table 2 Impact of centrifuging time and type of collection tube on 25-hydroxyvitamin D 
concentrations, according to type of assay  
 
  
CLIA/LIAISON®†  DiaSorin RIA†  
β 
Coefficient (95% CI) 
p-
Value‡  
β 
Coefficient (95% CI) 
p-
Value‡  
Centrifuging time 
 2 h Referent   0.63 Reference   0.05 
 24 h 0.008 (−0.068, 0.083)   0.011 
(−0.066, 
0.088)   
 72 h −0.041 (−0.106, 0.025)   0.052 
(0.012, 
0.092)   
 96 h 0.007 (−0.049,   0.026 (−0.028,   
  
CLIA/LIAISON®†  DiaSorin RIA†  
β 
Coefficient (95% CI) 
p-
Value‡  
β 
Coefficient (95% CI) 
p-
Value‡  
0.056) 0.080) 
Collection tube 
 No additive—
serum Referent   0.05
§  Reference   0.21 
 Heparin—
plasma 0.054 
(0.011, 
0.096)   0.019 
(−0.006, 
0.043)   
 EDTA—plasma −0.002 (−0.071, 0.066)   −0.034 
(−0.096, 
0.027)   
β coefficient from generalized estimating equations (GEE) linear regression models; 25-
hydroxyvitamin D concentrations were log-transformed  
Abbreviations used CLIA Chemiluminescence immunoassay; RIA Radioimmunoassay  
† Model adjusted for centrifuging time and collection tube 
‡ Two-sided p-value from the omnibus test  
§ Pair-wise test: heparin versus serum, p = 0.01; heparin versus EDTA, p = 0.08  
RIA 
None of the 25(OH)D concentrations in our samples were below or close to the limit of 
detection (minimum, 5.1 ng ml−1 vs. limit of detection, 2.5 ng ml−1). Although we found a 
marginally significant effect of centrifuging time on 25(OH)D concentrations, there was no 
evidence of a consistent trend (decreasing or increasing) across time (Table 2). Furthermore, 
we found no differences in 25(OH)D concentrations between samples centrifuged at 2 and 
24 h (pair-wise test, p = 0.91), the two most commonly used centrifuging times in 
epidemiologic studies. We found little effect of collection tube on 25(OH)D concentrations 
(Table 2). No significant differences between tubes were found in the sub-analyses of 
samples centrifuged at 2 or 24 h (data not presented). There was no evidence of interaction 
between centrifuging time and collection tube (data not presented).  
Discussion 
In this study, we found no evidence of a consistent trend across centrifuging times in 
25(OH)D concentrations, up to 96 h after blood collection. Neither did we find significant 
differences in 25(OH)D concentrations by assay type. There was some indication of a 
difference in 25(OH)D concentrations by tube type in CLIA/LIAISON®-assayed samples, but 
the difference was statistically significant only after substantial centrifuging delays (96 h), 
with concentrations in heparinized plasma higher than in serum or EDTA plasma.  
There has been little information about the potential impact of blood collection tubes on 
25(OH)D concentrations. Although there was a marginally significant effect of tube type 
using CLIA/LIAISON®, our finding should be interpreted with caution. The effect was 
evident only in CLIA/LIAISON®-assayed samples and was not significant in the most 
relevant centrifuging times for large epidemiologic studies (2 and 24 h). Furthermore, the 
differences in 25(OH)D concentrations by collection tube were not large (Table 1) and may 
not be physiologically significant. Our null finding is consistent with a previous study [18], 
which found no effect of collection tube on 25(OH)D using an assay developed by Mason 
and Posen [19]. Ersfeld et al. [14] also found no difference in 25(OH)D concentrations 
between serum and EDTA plasma using CLIA/LIAISON®, but the authors did not include 
heparinized plasma in their study. To our knowledge, our study is the first to systematically 
evaluate the potential impact of collection tube on 25(OH)D concentrations when using 
DiaSorin RIA, one of the most commonly used 25(OH)D assays in epidemiologic studies.  
A prolonged time between blood draw and centrifuging could increase hemolysis [10], which 
could impair the stability of 25(OH)D molecules. Lissner et al. [18] reported that 25(OH)D is 
stable in uncentrifuged blood until 72 h, using an assay developed by Mason and Posen [19]. 
To our knowledge, no previous study has evaluated the stability of 25(OH)D in uncentrifuged 
blood across time using commonly used 25(OH)D assays. We detected a marginally 
significant difference in 25(OH)D concentrations over time in DiaSorin RIA-assayed 
samples, but the absence of a consistent time trend in 25(OH)D concentrations does not 
support an effect of centrifuging time. Specifically, we did not detect differences in 25(OH)D 
concentrations between samples centrifuged at 2 and 24 h, suggesting that overnight shipping 
of unprocessed blood samples is acceptable in large geographically diverse epidemiologic 
studies.  
Among all commonly used 25(OH)D assays, DiaSorin RIA has been predominantly used for 
25(OH)D quantification in large-scale epidemiologic studies [13], but recently, automated 
technology such as the CLIA/LIAISON® platform has gained wide acceptance in large 
clinical laboratories in the United States. [13, 14]. Our finding that the two assays give 
comparable 25(OH)D results is consistent with previous studies [14, 20, 21]. Ersfeld et al. 
[14] reported a high correlation between the results of the two assays in 329 clinical samples 
(r = 0.91). Similarly, a recent study reported a strong correlation (r = 0.918) between the two 
assays using 390 serum samples from a clinical trial of vitamin D3 supplement [21]. In an 
analysis of 228 osteoporotic patients, Souberbielle et al. also reported a high correlation 
between the assays (r = 0.83). The authors also suggested that the DiaSorin RIA gives higher 
25(OH)D readings than CLIA/LIAISON® at lower concentrations, whereas the 
CLIA/LIAISON® assay gives higher readings at high concentrations [20].  
Several limitations should be considered. First, most of the 25(OH)D concentrations in the 20 
volunteers were at levels proposed to be clinically insufficient (<20 ng ml−1 or <30 ng ml−1, 
in the absence of agreement on optimal concentrations) [17, 22], and therefore, the 
generalizability of our findings to higher concentrations is not known. Also, this study was 
not designed to evaluate laboratory reliability, although with the blinded repeat samples we 
were able to calculate within-batch CVs, which were acceptable. Other limitations include the 
small sample size, which precluded some subgroup analyses and the detection of interactions, 
and multiple comparisons.  
In conclusion, two commonly used 25(OH)D assays, CLIA/LIAISON® and DiaSorin RIA, 
gave comparable results, and longer intervals between blood draw and centrifuging did not 
influence 25(OH)D concentrations. There were some indications that 25(OH)D 
concentrations in heparinized plasma may be higher than in serum or EDTA plasma, 
particularly when using CLIA/LIAISON®, but the difference was not significant within 
normal time frames between collection and centrifuging. Our study suggests no necessity for 
requiring immediate processing of blood samples after collection or choice of one type of 
25(OH)D assay or blood collection tube. Future studies with a wider range of 25(OH)D 
concentrations and larger sample sizes could be helpful in confirming our findings.  
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